<SEC-DOCUMENT>0001193125-13-428825.txt : 20131106
<SEC-HEADER>0001193125-13-428825.hdr.sgml : 20131106
<ACCEPTANCE-DATETIME>20131106060633
ACCESSION NUMBER:		0001193125-13-428825
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20131106
FILED AS OF DATE:		20131106
DATE AS OF CHANGE:		20131106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		131194595

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d624043d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2013 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K
if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other
document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under
the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security
holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;
No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to
the registrant in connection with Rule 12g3-2(b) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Novogen Limited</B> (Registrant)</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Andrew Bursill</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Andrew Bursill</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Secretary</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date 6 November 2013</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6&nbsp;November 2013 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Announces Joint Venture
Dedicated to Fighting Ovarian Cancer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6&nbsp;November 2013.</B> Novogen Limited, an Australian biotechnology company listed on both the Australian
Securities Exchange (<I>NRT</I>) and NASDAQ (<I>NVGN</I>), and Yale University, today announce the establishment of a new joint venture dedicated to the development of chemotherapy strategies to fight ovarian cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The joint venture company is CanTx, Inc and is based in New Haven, Connecticut. Novogen owns 85% of the new company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The joint venture brings together two fundamental complementary resources required to combat ovarian cancer. In the case of Novogen it is a drug technology
platform capable for the first time of killing the full range of cells within an ovarian cancer at clinically meaningful doses, but most importantly, ovarian cancer stem cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of Yale, it is the in vitro and in vivo test systems capable of evaluating the clinical potential of those drugs. The involvement of Yale also
ensures access to world-class clinical facilities and will expedite the move from the bench into the clinic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CanTx R&amp;D will be centered at the
laboratories of Professor Gil Mor of Yale Medical School. Professor Mor is the first researcher in the world to isolate ovarian cancer stem cells: those cells responsible for ovarian tumor growth initially and then tumor recurrence following
chemotherapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under this joint venture arrangement, Novogen retains full ownership of its drug technology intellectual property (IP) and will grant CanTx
access to that IP for drug development purposes only. Novogen separately will continue to exploit the same IP for a range of other clinical indications including glioblastoma, along with its newly-acquired anti-tropomyosin drug technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Professor Mor said, &#147;This is the future of cancer drug development with academia and industry working together for the benefit of the patient. There have
been no new therapies for ovarian cancer for the past 30 years and a fresh approach is urgently needed.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Current chemotherapy unfortunately
only does half the job. It is reasonably effective at killing the predominant somatic cancer cells, but by not killing the cancer stem cells. Around 70% of patients who respond to first round chemotherapy will eventually experience tumor
recurrence.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150;
ACN 063 259 754 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0) 2 9476 0344 - F: +61 (0) 2 9476 0388 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.novogen.com </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Our experience with the Novogen super-benzopyran family of drugs leads us to believe that this is the
future. These drugs show a high degree of activity against ovarian cancer stem cells where no other drug in our experience has worked. This program will be the first in the world dedicated to finding an effective treatment for ovarian cancer, with
the advantage that promising treatments are capable of being moved quickly into clinical studies in months instead of years.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Graham Kelly,
Novogen CEO, said, &#147;This joint venture with Yale brings a level of expertise, resources and firepower that is unique in the field of ovarian cancer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is a full onslaught against this insidious disease that will occur on two fronts. The first front is immediate and is based on our lead drug candidate,
Trilexium. A variant of Trilexium has been identified as a powerful killer of ovarian cancer stem cells and is being packed into a delivery system specially designed by Professor Mor&#146;s laboratory that is to be given intra-peritoneally (the
abdominal cavity) where it seeks out ovarian cancer cells.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;When anti-cancer drugs are injected intravenously, usually only 3% or so of the
drug actually reaches the tumor. With this delivery system, virtually all injected drug reaches the tumor, thereby ensuring maximum anti-cancer effect.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The second front is more long-term but very exciting and that is to personalize chemotherapy on an individual patient basis. This is the same approach
that we are taking with all the clinical indications we are pursuing with our super-benzopyran drug platform. As we make small structural changes to these drugs, we find that they change their target. Each super-benzopyran drug is highly efficient
at killing cancer stem cells from the one individual, but no single drug is able to kill cancer stem cells across all individuals. This leads us to conclude that we have identified for the first time a family of drugs capable of identifying
different mutations within a cancer.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The task now is to create a panel of these drugs capable of killing cancer stem cells across a wide
range of patients so that the appropriate drugs can be matched to the individual tumor. CanTx will take this strategy into ovarian cancer while Novogen will focus on a range of other clinical indications,&#148; Kelly added. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kelly said, &#147;We have an extraordinary wealth of opportunities at our disposal. With the super-benzopyran drug technology we are actively pursuing ovarian
cancer and glioblastoma as primary indications, each with the dual strategy of developing an immediate drug for clinical use followed by the development of a panel of drugs for personalized chemotherapy. On top of that we have our newly acquired
anti-tropomyosin drug technology with its applications across the fields of melanoma, prostate cancer and neuroblastoma. In the face of this broad range of opportunity, linking up with a partner such as Yale with its considerable clinical resources
and know-how, brings a greater level of certainty to the success of just one of those programs.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Ovarian Cancer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The American Cancer Society estimates that over 22,000 women will be diagnosed with ovarian cancer during 2013 and 14,230 American women will die from the
disease. It ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOVOGEN LTD &#150;
ACN 063 259 754 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16-20 Edgeworth David Ave, Hornsby, NSW, 2077 | P: +61 (0) 2 9476 0344 - F: +61 (0) 2 9476 0388 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.novogen.com </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol &#145;NRT&#146;) and NASDAQ (symbol
&#145;NVGN&#146;). The Company is based in Sydney, Australia and is focused on the development of novel anti-cancer drugs based on two proprietary drug technologies - the super-benzopyran chemical family and anti-tropomyosin drug technology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Trilexium </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trilexium belongs to a new class of drug
candidates known (structurally) as super-benzopyrans. Members of this family of drugs are showing high potency against both cancer stem cells and somatic cancer cells recovered from both ovarian cancers and glioblastoma cancers. Using the Trilexium
structure as a pharmacophore, variants of the molecular scaffold (analogs) are being created and tested against ovarian and glioblastoma cancer stem cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cancer Stem Cells </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cancer stem cells are thought to
be the tumor-initiating cells in many cancers responsible for both the production of the tumor mass and metastasis. Cancer stem cells have been confirmed in both ovarian cancers and glioblastoma. These cells are highly resistant to chemotherapy and
radiotherapy, a property thought responsible for tumor recurrence following successful initial therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact details </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dr Graham Kelly, Chief Executive Officer</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ROWSPAN="4" ALIGN="center">


<IMG SRC="g624043tx_pg05a.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tel: 61 2 9476 0344</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax: 61 2 9476 0388</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mobile: (61)&nbsp;0429 854 390</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16-20 Edgeworth David Ave Hornsby NSW 2077 AUSTRALIA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PO Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email:
<U>graham.kelly@novogen.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Web: www.novogen.com </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dr Graham Kelly, Chief Executive Officer</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ROWSPAN="4" ALIGN="center">


<IMG SRC="g624043tx_pg05b.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tel: 61 2 9476 0344</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax: 61 2 9476 0388</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mobile: (61)&nbsp;0429 854 390</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g624043tx_pg05a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g624043tx_pg05a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*@!\`P$1``(1`0,1`?_$`*X``0`!!0$!````````
M```````(!08'"0H#"P$!``$$`@,```````````````@!!@<)!0H"`P00```'
M``(`!`0$`P,-``````$"`P0%!@<`"!$2$PDA%!47(A8V&#%1-T%A&3)28E,D
M-&15974F9C@1``(!`P(#!@,$!0P#``````$"`P`1!`4&(1(',4%A(C((41,S
M<4(4-%)B(Q8V@9&QT7+24V-S)!4U%S<8_]H`#`,!``(1`Q$`/P"-?OP]]F'>
M/N"^KM&F6T]@771.4SS,G3)P1W#VFQK.&YM&T1DHDHJV=-IV8CTF#%=,1(M&
M1B"Q?#US@,5^I^['UC7/P&#(?^/Q+J+'@S_?;QX^4=UEN.VNP%[(/;_!TPZ4
MKK>Y\1/WOUTKDS"1;O#$`?P\-CV%$9G?O621U/`"H>>V?W*E.@/;_,M]C2KC
M3$W9Z9L4&P)^.QY+:7+)*UMBH$*8SF0@U&C:98D#P\[^-1*(^0Q@'@-E;IGV
M[K\69*S-B/\`LY0>/D8BY'BILP\1;LK*_N3Z%:/UCZ4:AM;$A@AUR-3D8<@4
M#DR8E)2YX663C&Y[D=K"]J^IK6['!7&NP%NJ\JSG:S:86+L==FXY4'$?,04V
MQ0DXF48KE_"LSD&#E-5(X?`Q#@/)BHZ2()(R"C`$$=A!X@C[:ZV&=A9>FYLV
MG9\;19V/*\<B-ZD=&*NI\58$'Q%5KGE7RTXI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*5\YGWS?;AF^I'<25M.1T*45P;L,62T.A,ZC7GSN)I=F(N@&B9\5O%,3
M-8QK'3+U.1CD2E(F2-D4D4_'Y=3PB[U,V=D:=KISM,A=\++N]E4GD>_G'`<!
MQYAX&W=6_/V3>X[3.H/2Q-!WCGQ1[NT/EQY6FD56G@L?D378W8LHY)&[3(C,
M>#"H:^WMT0NG<#M/0,HMD!9J9E,<#W0MQNTS$2L!&U7'J45&3N+I26?MFK=F
M]F$12BVA_,(I.GQ%1#TTSB'";)V7J6X-PX^%/!*N)SAGNK"X!'E'9YG-E%N\
MWK*'N7]R&T.C72'5=WXVHX4NL+CLF,HE5A\UU/G>Q-HXE#2R7M^S1N(-JW\Z
MY[H_91?1;(UZXZ:_R#`H%5E4L=SR`JM%&.@L]J4>UKU:4`)NKRT@DO+1\>5V
M9$5Q3;`L5$@`5,.;6=O]+=M8FCX\.I8ZRY@C',>9P/[*A6`Y5](X<0*Z#'5?
MWP]9MP=0M5U;:>KOB:#-F2-$K0X\CL.8WE=I8G<R2F\D@+$!W8#R@5LE]IGW
M%]/U_3[-@G9"^J72QVM@K:,FL\G'5Z'=F>P;3QL]%4)7XJ':.CKQ2/U1B)DA
M4`&SPICB'I%"R^H^Q,#1\%-6T2(QXR-RR+S,W`]C\22`#Y3QXW'#@34BO9[[
MH-S]0MR96Q.I6:N5JTZ&7"F*11%FC!,D%HE16NEY$\MQ\MP2>90.A+F%ZV-4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE<\GNO\`N.:EDFLUW".ME^4ILU3&`3VM
M66-C*],KGEIUHDK7*00+!$R[5L,=#J?47IDR`H)G;8GF*)%"CFSIKL7!U7#D
MU;78?F8K^6)22.\@OP()X@@?9\#6MCWB^YW<VR-SXVP^FNH'$U/$3YF;+&L;
MGGD"F.#SJX'(AYWX<3(HN#&16KJ&]Q/LEHZ[W,^Q>Y62PXAID-+Y[HQ&\%5(
M=]!05L9*1:=Q8/:Q7X>645ITBJA(+M`6%*18H+M%"&(N(<R%F;%T/3XO^0T/
M%1-3QV$D?%CS%3<I9F(\PN`?NDAAQ`J)FW_<]U-W-FMM7J/KF5D;,U2%\7)\
MD2M$LRE5F4Q1HY^2Y61D!M*BM$05D-09NM-L&=7"S4.U-TFMBJ,P[A)4C<X*
MLUUFI@^7D8U<`\KJ&F&1TG;%<OB1=FNFH41*8!Y>>!F0Y^)'F8Y!B=0?L/>I
M'<1V$=QN.ZHX[HV[J&U-?RMOZFO+EXTI4VXJP[5=6X<R.I#(XX.I##@167>O
M*RU&L;[L,X7<LX[`U8FQU[Y9==DK9=AE3/$,HI2#I`Z:OH+2C1Q,RY"CX*5^
M&>I&^*Y`-P^XO]YCKH2J"^7</>Q"Q`CG<?SA!V69E/9>LA=)`^W,Z;J=DM)%
MA:#RRPE25^;G$DXD`8$<"ZM-*O'F@@F7@Q6\D/\`%E]P;R>4>P!?.)?**A<N
MR0/QB'AYP*-($H!YOCX?$.<#_P"+-FD<8)!V7M(_V$\6/?QK*Y][WN#+7&J0
M<M^S\)B=GP^C73O[>W:]'MUUQK-ZE7+/[DUI0:5K$>U31;%1N<0W0,>:08H@
M1-K&VV,60DVY2%!)+Y@Z!?BB8`C]O+;DFV=<DP+'\,?-&3WH>Z_Q'9\;6/?6
MU?VY]7HNLO33%W%D,G[Q0?L,U%`6TZ#Z@4<%69+2`#RABZ+Z#5A=".[-L[/&
MO-7UFJU:D:!%GDKUG[>I+2IH.]8>I?+?FL=9683;MV^&QUB[T.1B[`B0PHME
ME&2I0*F\2+RU`:SN#?MJUJ3WGUG3,;ZN-L\S:D6'L_VAB-"L4?7WLM.0N1YG
M1LSL"\-;]0O,BD2:M2E<BEWL2Q:Q[4#/9:7E$T$U4$@571?TTO\`"KEM>[]Q
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MT:]=9.L=2LIK\](0TH[QZT_=FXZ36*B^<-UG\5/Z37IB&IXZ`RBE#`HBT@7,
M:D]+Z0.%4P]87&G&K>#7^YFH[IV;SS$776*L5'`KO2J,Q<ZI3]7LECGGEIR*
MD:4O).W-2OU:BD6S9U;A;$231\_IH@)C>(^(J<:IM@[J:!GG=>&Z]Z!5Z2..
MNJEBE>GM-A`L+:9K.Y[D&CES]M*-WKQ[%(9U<IC+GL&Q,8`>(S4@P345.5;B
ME^/A7I^]#0_\2_\`93^5*7]N?M;^>OS;XSGYU^I_EKZU\GX?4/H7R'S'X/\`
M=_4\G]OC\>._PI?C:N=GW4^N$[@';*YS+A:1DJ7N4A+:K3IZ167>.%7\H\(-
MSK#I^N8YU7=:G'("D0QA,6-=-/Y"`2KZ9Z[!K&@)C@!<S%41LHX"P[&L/B+<
M?CS#NK1A[R>E^I[!ZNY>M2&2;1=<=\N"1B6L78F:(DDGFBD)'^FT1/%K5`R@
M4.QZE>*GG%0;HN;-=IQE7XDKDX)L&JCPPBZE95<WX&L)!QZ:SU\N;P(@S;JJ
M&$`*/+VU+/@TO"DS\@VBC4GXD]P"CO8G@H^)%1MV?MC4MY;FP]M:4`<W+F5`
M2>55%_,[M8\B(MV=R+(H+'@#4FM4[*Q:-R7K^;T7%+EGM"A*QF5+NVG8I0[_
M`'V\5[.H!A4V=RL5GM,7(3+@;*>,.[9-3J>G'1JC=HF4"H!RT]*VM))B#)R\
MG,BRIF:1DBF=(T+L6Y5"LHNM[,;>9KMWUG?>76^'"UHZ/MG2]"SM!T^*+$AR
M<W3L7)R<A,>-(1-+++&[GYG)SHEP(HRD(%HQ5)>W1[ON/V:IEKM'JEPR*4E-
MIA:_F5)KV=UZ]4IS$15=TY1_6:NS8QTM>,]CHQC+M'8D,Y&`"6(/X$"ASW0Z
M<NW-53,:6>;%GM$SS,9&1CQCLQ)(1B2A!X%^2W$UQV;NB?JWL7+T=,7!P-<T
M=WSDAPH(L2')QRJIDEH851'G@54E5[%OD#))-D45$T1^'\RC_F_'Q#^X?X<O
M3B+6MS7%OY:CIW^-=2GL;]=;'1,GO782R.I5@CMSF,BJ=63++(1J].I+J410
MN3N/-Y2*R$Y-2#M)FJ8OB6/0*H01(Y^$;>K6MX^;JT>D8UF7$!YG[3S-:Z@_
M```G[0/NUN)]@_3'4]K['S-^:H\J#6V58(2;+\F!F'SF'>SR%UCOZ55F!(EK
MTQW/+O2.EW5WM%3*I9!U?JQH78":LM-3A9)M:=`Z[7O?-`;;CGJ4"Y1;2$A(
MK5=JRM<$@*1SN)FO,2H@(.!\V(NZXJ?@O;QJU^MB=DZ\9ST([;2E)OEARF+P
M?;,"VI.`I-HF+KF%:TC78C2Z#K3G/6,8K=9"JM9:E_(S9&K%=ZP:R:#L4#(H
MK"10?&I.;+LM+[WS6'8EUL&RZ#7(3?\`'MHV?6VM/ME>SC-J-BENCM-;0Q;E
M9X2(C9O1KS9Z_'Q;"'C/G';=NLZ=.P;)-P%15;WX"L*VZC6Y/=]3]OEM6;$I
ME'83M-2NU2UA)`31ZE'=>)QFMK'8:E+V%%H->8'LO8',CPQV`KE769WLQO3$
MA3#QX53PJ0C73(7I-V@[/O=R8V.N8CV:MM&V?.=L9UBS6JE1=UC\RI^5WW+M
M`E*S%2ZE%ET34%E+0R\BDWCI!F^613<?,-C)&=E5[#6`^P=,M7N4SVBVC!8>
M9CLUS#J_I%`R;2-`K$]18/:-YT"^93H;&+JT=;HN)GWF855+%F3*0GS-$V+I
MY,F(S,X(T6/QVU3M[*O[<O<UBC]=;>PS9CHV3]UBQ$$PA\#ON(Z!*W6#O:U@
MAF4[#-&(5*0J5WB4&9W@MI:.>.XIRV`K@BX%_P`E>JWX>-8<LQNIT'V_[S..
MT\_M=,D9C4<K?T<]$LG;NEQ$]5FW73*F3R4(.!/8NMSJC>?;.FPN%Q6=)F1%
M(3`4A2\53A>L^GR*J]H>Q?=FHR25D1S+:>G'30E0O1(J>BW+-\69[!V*I6^M
M2,TT9+I7.BRRD9,(%4$'K!ZDW,N0AA`!=]5[ZU-?<KM+^_;\^?;"V_NA^S/[
M4OJ'Y$LOV[_<Q]#^W?W0^N?1/H'VA]+_`,X^9]?T/HO^S^?U_P`/*=]Z\;F_
MC73GKN!XQOD;#Q&S9I4M(CJ\_6E(-K:HI&2+%/W+8S-RY8G/X*MSN&IO(H!3
M`!P`/$!\H>'*:;J^IZ/(TNF3/#(XL2MN(\;@U9^\^GFRNH>+#A;TTZ#4,;'<
MO&).8<C,+,0496L0!<7L2%)%U!$8KU[<G61SGFE06/992<8T.XYW<*1!:33H
M=&.L%=&TQ"\8Y^7?`1PNA'R:"@M)`J(%57CUET2G*"@CRX(-\Z^^7"^J3ODX
M4<JNT;6LW*;]P%R/4MS8,`;<*Q=J_MKZ8)M_4L+9FFX^D;@S,"?'BRHC(7B,
MJ%38NSV5P3'*5`<PO(BL.8UQ46>JV&BV6QT>VQ2\':J;.RM7LD,X(8JL9-P;
MQ6/D&GXBE$R1'"`BF?P\JB0E.7Q*8!Y++"RX,_"BSL4J<:5`5([+6K0ON30=
M3VOKV7M_68VAU3$G>*1&X,'1BK`W\0>/8:GO[777:P]@>V5.4:*OHZE9/XZ#
MH\PU*`$6A@(YB(^C*'4(=!9/0W#I5B[;G`?7A@?AX"`<LKJ3KF-I&WWC:QS)
MQR1KXGC\S[8^U3^D%'?4D_9[TSU+J#U;QLN-GCT+2E,^6X['C/E_#FX((R2?
ME.I]41E(ORD5TZ#[:'0T2>G^V#,P)Y1)Y09210`HAX"4/+)!X!X?R_AR.Z;S
MW3&GRTSIPEK6N/ZJVW__`#GT.YN;]V=+YKWOR-_>J9U>K\)4H&%JU9BF4'7:
MY%1\'`PL:@1K'1,/%-4F,;',6R8`F@T9-$")ID#X%*4`Y;DTTN1*T\[%IG8L
MQ/$DDW)/B367M/T_"TK!ATS38D@T_'B6.*-`%1$0!515'`*H``'PJL<]=?93
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*5QJ>Z7_]V[?_`$&_C1/^]?H*N_JW_P!G
M_P!=_P`/Z')&;"_AF#_L/O>GT>MO1X5I_P#<_P#^ZM8_A/U0_6^M^6A^M_F?
MI5M6]BK^DN\_TK_J;`?H/]1?I)M^JO\`I7_*O]/YSEB]4?S^+^;^F_UNSU#T
M>/Z7ARU*/V1_PIK/_1_G8OR'K]#_`%OU/\'];Y];U>8MJ;M.*4XI3BE.*4XI
/3BE.*4XI3BE.*4XI7__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g624043tx_pg05b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g624043tx_pg05b.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,0!D`P$1``(1`0,1`?_$`+@```$$`P`#````````
M```````&"`D*!`4'`0(#`0`"`@,!`0$`````````````!P8(`0,%!`()$```
M!@$#`P(#!0(+"0`````!`@,$!08'`!$($A,)(14Q%!9!(Q<8"G$B46&!,D(D
M=3=WMSG!4G*"LC6V.!D1``(!`P,"`@8%!PL%`0````$"`Q$$!0`2!B$',1-!
M42(4%0AA<8$R%I%"<B,SLQ=2@K)#4V,D-'0U-['!@Y,V)?_:``P#`0`"$0,1
M`#\`O\:-&C1HT:-&C1HT:-&C1HT:-&N$6?-!3WPV(\:11+ID5HW;2%K4,L9&
MHXTAGFXM9*[RR/4H$G()E$6$.V`SY[MU&%NANX+*K+C1&)_$.;<VV'8E8NE9
M;EQXK`A_-7^LE:B)X#>]$*KS?<I6Y6>WW"H!D^8QHLET:E;3&PO]V2]E%3YD
M@!,%I%6>:E6\F*LP3]MHG(3(A3LBY<8X8KQ2E1`M$K3&?O<L4"@"KI_9+`JK
M#5LRQ@$Q6T>S<G1`=OG%!#?7JQ^4XCAZ2G'ODKSQ_7R-'`GJ"QQT>2G@6D=0
MW]FNN1R#BO=[F(-JO(8N-8<"G^!MDN+Z44ZM)<W!,-M4]1'!#*4K3WE_'3;K
M)X[WU@4-(&Y6<@E)LVY_<YF=1ER=T1ZNOY9!2*.4O5_1(J0`^S;4ULN\,=FH
MA&`Q`M1^:D93I]9W?E(.DOFOD]NLNYNVY]R\Y,]?,FG$HKXUVJ8B.OH#CZ*:
MXG/X^\B7%KKL%'R0IR$H,6`KNX.41<S\JG'(&$YP<5V665L:9>V`B(Q$FNH4
M-Q$FP#J36F7[.<Z'NF4LAA\L_02*0B%CZI$`C/\`YHU!]>EEEN(_.+V*KE^+
MYH\OXG![3P2JT\HC7J0UO*3<`4\3:7+L/'92NGB\4^:%$Y+LEH11K]&91AVI
MEYRD/G'=!TBW,"+J4K3Q0B"DE'HK"`+)'(1TT,/2H02]*AESS[MKE>$2BZ#>
M\X*1J).HI0GJ%D45"L1X$$J_BIK4"QG8/YE>*][+9L8T?PWG5O'NGLG:NX*:
M-+;.0IDC!^^I598B0'6E'9Y^EMJRFC1HUKF<Q$R*JZ$?*1SY=J/2Y19O6SI5
MN;<`V7305.=$=Q_I`&MCPRQ@-(K*I\"017ZJZUI+%(2L;*S#Q`(-/KUL=:];
M-:I">@W+PT>VF8IP_)N!V*$BT6>$$N_4!FR:QEB[;#ON7[-;6@G5/,9'$9])
M!I^7PUJ6>%G\M74OZ@17\GCK:"(%`3&$"E*`B8PB````&XB(CZ``!K5K;X:^
M17"!BG.59(Q$P$RARJ$$I"@'4)CF`=B@!0WW'[-9((-"#4ZQN6E:BFF[<E,Z
ML<.X+O&2:^[C9J:8MT8.J-VSE!^@ZN,ZY3B8-LJ#<ZI%`;O'(+JICL)DD3!]
MNI?PKB\G)>46N&N0\=JS%Y30@B&,%Y"*TI51M!]9&E!WQ[F)VN[7Y/F-ELFR
MT<:PVB=&#W<["*!:>D*[>8R^E$8:CM5X_P#E6Q<=FSXK9%X<1U5LT%"6W(4G
MGVM9.G<I6/,4XU.\O\I+R]6+[8XAD7ZI&T:GOUHM4``0`1'=D7G*^TV?G>;E
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M2FW%:))-33R$,J[`&J4LK$@L5L97[LJPE$W[N^H/=7G84VL@L[/D@O#&WEEI
M+;:'VG86H:[=U*TZTK34RMK?O*+B,W=Q@C:[QOVK/NVUZ[:K2M/"OY=3$:3.
MFKJ*GG)QM>U-XWY>8%0^F\EXZ?HV:YL8A$$FUCC&A@%[9#LD`*FI(LVPF+)D
M`O3(1QU14W.GN=\]KN:17\9[=\L/GX.\0Q0LYJ8V/W8]Q_-)IY1\8Y-NWH>E
M"_FC[+7.`N4^8?M0GN7-L-*+F\2$46XC3[]P47H9$6HN12EQ;ER]76KN[_,W
M4_RM_F:[9?9_H/ZD]JZQZOJ/;VWZ8[G\[N_57]1Z_P#G^&E[^",A^._P/7_%
M>]^5O_N_O>;3U>5^LI]FK"_QOP'\"OXW4_\`S?A7O/E5Z^\?L_=J^-?>OU&[
M^=X:JJ>1'E9RU\FWD$>^-GB%=)"BXKIMCFJ397L3/R-;B[A+T]$ZV3+[DB>@
M3&E'-!ISANJR8Q:/<3=KH`?MK.'*!$K2]M^(\/[6]NAW.YG`MQEYXEE0,@=H
MUDZ010HWLB60$,\AH5!I555BRRY[RCE'<7G1[>\3F,.,AD:-R&*J[)7S9)67
MJ40@A4Z@T!`9V4#ZW7]-]S#P6TJF1N)G+QO9<NQTU"C)(HDL6#Y"'%R];(O+
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M=0L`NHN,B_IA[W2<<3=WQ/S*DK'F*N0;N?CH23H#NFP\_,1K-5\,7'6Z+OTK
M-P+EXNEVVSI5!<I5#%%0"%ZC`U\;\T^/OLDECE\(L>%ED"%A,)&16--S1M"J
MN`#5E!'3PKI9WWRX7MECWOL7EC)F(T+`&$QJ[`$[0XE8J2>@)4_33Q&5XK^>
MN:^1/CQ\C_'S-]NG[Y/X)XMY'LF/[W8W[J1N'T?8\<7^*=U>?GW"RDA+*U>7
MATC,'*ZBCH$'1D3*"1!(`^>Z_;[!\;[D\9Y%@H8[>WR&6A2:)`!'YB30L'1`
M-J^8K$,J@+5:@59JY[:\XS'(.`<AP69E>>>RQDS12L27*-%("K,?:.TA2I))
M]HBM%4"+?Q5\,.7'D2K^5L)4?D38<*\::S-5FWY@DS.9N63LUREHQY$U:!1@
M8Z7A'-J<)P\6Y7,@\?I1K(A05,0ZZJ0"U>['-N'=MKBTSM]C8[[E$T;QVXHJ
ME(U8,[[V5Q&-S**JA=O`$*&HN.VG$^6\_AN\/:7[V?'8I%>8]2'=MRHNP%=_
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MB&V.ZMXY0/4)$#T^RM-0Z\Y/]9KP_P#]C<K/\N3Z='`_^$N9_IV'[[2EYI_R
M[Q/]&\_<MI:>0?*6?N#'(?#G.2-O=^N7"U^XB\0<N,*J.UIBMXPC;$\;1M8S
M[38<$S*1BL;(G02E"IB!5#D(0/5\H=/G]N\3Q[GG'+W@DL%O!S=0UQC[F@5Y
MV0%GM)&_.W+4I7P%3_5@'I\WR.;X?G;7E\4T\W%&*PWD%2RQ!CM6>-?1UI6G
M4L`H_:DJL?)ES*NM/Q]B/CEPYEFUDY;<X'#>L8'E8!ZV=M:1CZ1:H/+9GMV^
M0!RFTK]=KC@56#X0%,%3&=$ZRLU2#XNV'"K&]R-YR3FB-%P_!`O=JX(,DRFD
M=H`:$N[BCIXTHAH7!UZ>X/++JVL;7!<482\ERY"V[*>B1$5:XJ*T4+7:WH]J
M05$;#4BN&<7R6-\+TG%=VOMJS--052;0-QR%D-\:7L=_EW#<_P!13,RHMN4J
M$J]<K=EJ&Z;9H)$"B)2`(KC-96/)9R?+V%O%8Q/-OCBA&U(5!]A5IZ5`%6\6
M:K=*ZF^/Q(@PB8;)R/>@PF.5YO:,VX$2;JU]EJD!36BT6IIJ,3\'Y?\``+\K
MO=<^Q_GN_#KN]2G5^''<_$;JW_W?9?O=OAW/X]/?\10?BW\=T7WO\*>\>C_,
MT]V_I]/JU^>G\.LA_"7^!>Y_A?\`%7X=7K7X=7XC7_T^U]?TZ@3\'>](\T/)
M.H7TP-;L\KO)BMM$I`=GCBT1F5Z[-3#='N[*'=J0T0\7';<PHI'-\`'3>[\4
MO^R.+O,?UL5DL7)'@(VMW52?HW,H^LC34[+@V?>#(VU[[-T8[M.OB9!,C&GT
M[4<_4#J\-JB.KH:K,>9+R7\J,<\F<0>/OA&\8U'+.46M)-.Y!58Q#V>&;R=8
MG5=I5.K"U@;/X2O("1K\Y)2:K=9<B:Z1412[:ICVA[+=L.)9/BU[W%YTK38>
MT,NR$%@NV!`\LC["&<]=J("!4'<&J*5U[M=Q>2X[D5IP;AY$64N?+W2D*3NE
M?:D:EJA1X%FI7VA1EVFN%_\`,/S4C`JR%C\ODHP>>VN'4M&1Z5YDX]N8&YU7
M35O(G"'.Y0*'44#_`"B/IZ@0/AK[_BGV1%P([;AR,FX!6;RE)Z]"1[5/JW'Z
M]?0[=]V/=S)<\G=9-I+`-,5'3J`?9J/L'U:AX\)P&#$/E]`YP5.'!*Z@=4/4
M%3!"9*`R@#]H*&#?^73J[XT^-\-H*#\01?TX=)[LY487E=34_!9NO\Q]2B?I
M5?[E.7'^*F-__"I+2G^;+_>\/_I)OWBZ9WRS_P"SY3_4Q_\`236\_50_^N?%
MG_'&S_M_N[E/36CY3O\`Z7*_Z%/WPUN^9?\`^=Q_^K;^B-3C^.!ZTD.`7#)R
MR<).D/RT8;;]Y$X')WV=%A6;M$1#X*-G:!TSA\2G((#ZAI$]SHY(NXF;24%7
M^*7)H?496(/V@@CZ#IO]M[B"ZX#AY;9UDB^'PK534;D0(X^M75E8>@@@^&H^
MN<G^LUX?_P"QN5G^7)],3@?_``ES/].P_?:A/-/^7>)_HWG[EM2L\J[-A"G\
M;LVV+DF2+6P1'8WM'XI,YA$KAI)U-W&K,7\,DV,=,[J4F1<E:,4DS%75>K)%
M2$%!*.E'Q.VSMYR:QMN,;QR!KE/(*FA60-4,3Z%6FYB>@4$GI730Y-/A[;C]
MY-GPIPP@?S017<A%-H'B68D*@'4L13K35:3P1(P./N2DI`<CZQD6MYNR?QSJ
M=BX%/<RSC:?<)<)T9BRR#+'U(<B1).-LL8F"3U^@F5-9>/3,<B*")%06L]W^
M:?(\92XXS+;2X*UR4B986Z%!\3VHIFE'YR'JJL:@.0"S,5VU][,+#8\@:+/Q
MSIE[BQ1L<T[!O\#N=O+B(^Z:>UM%*HK%40!MULR4DF4-&2,Q)+D:QT2P=R3]
MRH(%3;LF+=1TZ74,/H!$D$C&$?X`U46"&6YF2WA!::1PJ@>)9C0`?6335E+Z
M]ML;939&]<1V=O$\DC'P5$4LS'Z`H).N3>PQ/T?]>>WJ^Z?-_C%\KT!W?J7Z
M)]L[7;Z=^OVG^K[?'JUW/>;KXA\*\P>1M]TKZ/*\[=6OZ?M:@/PK'?A[\5^2
MWOOF?%]E.OO/N7E;:4\?*_5^NNJ\'E)\.?(>P<EF_/KQTV%.!S:K*L;5<Z(U
ML3&G6`UZBV8,AO\`CR?EU&];7=6&.1*C,1$DJW0>*"HH!U@<K(:L3VH[T\;M
MN+GMYW)B,F"V&..4H9$\IC7RID4%P$/6.1`2HH*+L#:6O<OM-GKCD(YSP&3R
M\T&#O&&"-Y@'[2-F(3VOST8J"2Q]K>5#1K.P_4P\MDZ[B2T0UEPQ"QLY"R,I
M>HY;&F$FJKZ#?MWK"8LELJ,NZL<NP8/FQ')V4.W40='('4U5`"E"86K_`"O<
M0\W,6SQ7TS(P6(B>Y-'!!5(Y%"*2"0&D(*_RQU.HQ<Q_,/R@1XNX1[2%74M(
M#%`"5((9G3:Q`(J1'4'QVD@:<[Y0O$SS?RK.\;>8>"[W7\H<P<04"@5[+;BM
MIQ>,GMMO.-Y%>P5G*V-FD^_^G$)!E(NE$74<Z<-2+IHH*(I_O*-BQ;M5W>X+
MB;?)\+S]O):<,O;F9[</NG$<4RA'@F*#>00`5=0U"6#'H&,A[E]KN892;'\L
MP<ZW'*[2&-9=NV(O)$=RS1AB$W`T!!*UVJ57J5"#:7;]2ARDA'.`K%B^G8#K
M]MCU:O=\URU9I])DH^O2")F,V]3D6EOLKDKQTR44+O`0X.@,?[@R'HH3WO8_
M+)Q.<<AMKN?(W,+>9%:J\DH9U-5%#&@H#3]M)M_E;O`^1;OY@^20G!W-O#96
M\J[)+@JD9"GHQKN)ZBH_5)N'YM/'2!\5WC8YL<>\;>2NMY8P-/5%_F/B-:L:
MXH2=6"CN_K6WN(J],F$.P]IM4D2/5>'DFW29X9ND7NAU'#8VW3[L=SN"\BRO
M&+K$9".:*RS$<]P0DH\J,-$2QW1K6E#T6IZ>&N;VT[=\QP.+Y%;Y6R>.:\Q<
ML4-6C/F2,K@*-KD`DD?>H/IT_P!_3U<.N2W#[%?)"`Y)XJEL5R]TR#1YBKLI
M67J\N>7C8NJOF$@Z14K$Y.(HE;.U2D$%3)F$1W`!#UTNOF,YIQ?F>6QEQQB[
M2[A@MY5<JLB[2SJ0#YB(>H!/2NI[V)XGR'B>,OX.06S6TLTZ,@+(VX`/4^PS
M>L>--;?]0=Q"Y(<O\(\?:OQNQ;*Y2GZAEB?L-CCHJ7K,0I%P[NE2$8V?*JV>
M;A&ZI%7ZQ4P*D<YP$=Q*`>NM7RZ\RXSPW.Y&ZY-=I:6\UHB(S*[;F$@8CV%8
M^'7K0:V=]>*9_EF%LK7C]LUS/%<LS`,BT4J!7VV4?DT\3Q\T+)O$+`>#<,9:
MCY)O57V,<?K)NWJS-^YQ!E1Y6XT+UC"WN8MP\8(0+VR"JO$2::@M/F%%6RAP
M.=N96-=R<EA^>YN]SV$9/BD5Q*K*`0+JV5V\FYB#`$R+'19HR-^T*ZB@<+%^
MUF-Y%V=E'&.1^;+P?*,MS;SM1CC+ZX`:ZQ]T5)"6\LY:2SN.D8=W@D8.T1D1
M7+;`68[YY1_&9FVGT&7GL4X9B^1"&4+JS7BR1=-5MU'-&5LDDBY?H2*PRS\>
MVG\N@ML/J;I#UUCA_(L+C^U'*<%>W"1Y>^>S,$1#;I/+EW/0@%1M'4U(TQ^4
MX++7W<GCN9M(6?&68NO.D%*)YD15:]:]3TZ`Z3'-/`6>^>W+O#_&RVX^L%0\
M>^&G,9FC-UTD7<:W8<D<@Q)FSJG8BAV+254F5JC#.7)3R*CAN@DL?YH2B*C=
MF<_JX1R'C_;_`(=><GL[B.;N+>AK:UC4,390M427#$KM$C`>Q0DCV/0T@&KE
MN$S7->46N`N8'BX1:D37#DBEU(`"D*@&I05H:C^T/1EB)[!Y.>%ECY&X=J&0
MN/2J--Y<<4II'*G%ZS18-(T_O<$1LK)XP<G/V&05F]QD>1I\NL)&A72;?N[-
M^\4W%[6\WMN-9F;'<C!GX?ED,%\C5;V7J%G'B=\3,6J*MM+;?:VD=7N'Q*?.
MXN*^P?ZKDV-82VC+0&JT)A]`VN%%`:+N"[O8+`X=:Y$Y#Y8P&),#2V-9W$V4
MK!#Q4[S%JC]PR=DQ)"03I(MFH;:8B'\JP>N<C2;4&[(2.#JIP[S[\I%S*D1[
M!XICN#^^\Q-REWBHW9,2P!!NI'!\N<HP4A;=3O;H`94]DE:%D9RSN%>]UN0V
M'8O`1/'DI-DW)9$-4L;*%P9;(2*2#/?LJPA:[H[>1MZARP24KMDZ.UT$[?3T
M=OI#HZ-NGHZ-NGIZ?3;X;:2M36OIU;;:NW90;*4IZ*>JGJU[ZQKZT:-&C1HT
M:-&C1HT:-&C1HUS/(=#D[0V]QJ5H<4JZ,VRJ$?,E9(S,')-SE/UPEQK#LQ&=
MC@''6("3K0=MQ,)VRZ)A-U=K$92"QD\G(0+<XUB"R5*.I_EPRBK1R#IUHR-0
M!T8`4A/,.*WV<@]\X]?/C.2QH5CFV+-!(IK6&\MG(2XMVJ:BJ2QU+0RQL6W-
MDDN465,/`:/SSQRN?R+(.T3(6#$@R#1)!`FY$W/M2ZD=8ZP!R$W^7=E4,0/0
M#F`-]3:WX-@>1#S>*9FV\UNON]]_AYU)]&\;HY?TD(KZAX:2-]WSYYVZK:=U
M^&Y+W6+H,AA!\0L9%'0-Y3&.YM00/V<H8CT,1UTB)'R?8#03.G#U/,D]+=.R
M40VH?R;DZP_S45#/I1'MF$1`!Z2G_8.NM#V-Y:Q!N+C&Q0>ES/44]?LJ?^VH
MO>?/)VFB0IC\?R2[OZ=(EL=C$^@'?*M/L!USE]E#G)RP,,!B_';GC3C&2^YD
MK_;Q=(6]>+6V*J>+,Y;L9`BQTRCTECFA3`8=OG2!^]KL18/M;P&EWG+Q<WG(
M^JV\-#"&'ANH64CU^8]/[H^&H;=<Y^:/OZ?A/!L._">$3=)+^[W+=M$?$Q%E
M20$CP%O$#4T]Z4==/JX]\=Z'QRI@U:GIN'\E)KEDK;;Y7I5L%NFQ*(*2$FN&
M_;03$Y@;MRB*:!3#ZF.910ZLY?S#*\SR?O\`DBJ0H-L42=(X4]"J/2?#<QZL
M?4`JBT_:#L]Q7LUQKX#QT/->SOYEW=RT-Q=S>F25O0!4^7&#M0$^+,[MWK44
MTU]&C1HT:-&C1HT:-&C1HT:-&C1HT:-&L>G1I+H?]]5_XE/^G7N;_*#[-<6'
9_=&^W2G^T?Y/]NO"-=OT:\ZSK&C1HU__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
